Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Jul;38(7):1501–1506. doi: 10.1128/aac.38.7.1501

Bay Y 3118, a new quinolone derivative, rapidly eradicates Listeria monocytogenes from infected mice and L929 cells.

T Nichterlein 1, M Kretschmar 1, C Budeanu 1, J Bauer 1, W Linss 1, H Hof 1
PMCID: PMC284583  PMID: 7979279

Abstract

Bay Y 3118 is a new quinolone derivative with pronounced activity against gram-positive bacteria including the facultatively intracellular bacterium Listeria monocytogenes. Bay Y 3118 was tested in vitro and in animal models of listeriosis. All strains of L. monocytogenes and other Listeria spp. were highly susceptible in vitro; the MICs for these organisms ranged from 0.062 to 0.25 micrograms/ml. Bay Y 3118 was rapidly bactericidal in vitro, with a postantibiotic effect occurring for 3 h after removal of the antibiotic. L. monocytogenes was eliminated from infected L929 cells treated with Bay Y 3118, suggesting a bactericidal effect on the listeriae in these cells. Immunocompetent mice were rapidly cured by treatment with 4 mg every 12 h. Concomitantly, the levels of interleukin 6 and gamma interferon in mouse sera declined rapidly. In immunocompetent mice, treatment with 2 mg of Bay Y 3118 every 12 h resulted in a greater initial reduction in the listerial counts in the organs than treatment with 2 mg of ampicillin every 12 h. Bay Y 3118 completely eliminated L. monocytogenes from the livers and spleens of chronically infected nude mice. However, some of the bacteria reappeared after the cessation of therapy. In conclusion, Bay Y 3118 is an excellent candidate substance for the therapy of infections caused by facultatively intracellular gram-positive bacteria such as L. monocytogenes.

Full text

PDF
1504

Images in this article

1504Image
on p.1504

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bongaerts G. P., Hoogkamp-Korstanje J. A. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections. Antimicrob Agents Chemother. 1993 Sep;37(9):2017–2019. doi: 10.1128/aac.37.9.2017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bremm K. D., Petersen U., Metzger K. G., Endermann R. In vitro evaluation of BAY Y3118, a new full-spectrum fluoroquinolone. Chemotherapy. 1992;38(6):376–387. doi: 10.1159/000239031. [DOI] [PubMed] [Google Scholar]
  3. Fass R. J. In vitro activity of Bay y 3118, a new quinolone. Antimicrob Agents Chemother. 1993 Nov;37(11):2348–2357. doi: 10.1128/aac.37.11.2348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hof H. Treatment of experimental listeriosis by CI 934, a new quinolone. J Antimicrob Chemother. 1990 Jan;25(1):121–126. doi: 10.1093/jac/25.1.121. [DOI] [PubMed] [Google Scholar]
  5. Hofmann H., Tuma W., Heinz F. X., Frisch-Niggemeyer W., Kunz C. Infectivity of medical staff for hepatitis B. Infection. 1988 May-Jun;16(3):171–174. doi: 10.1007/BF01644095. [DOI] [PubMed] [Google Scholar]
  6. McLauchlin J., Audurier A., Taylor A. G. Treatment failure and recurrent human listeriosis. J Antimicrob Chemother. 1991 Jun;27(6):851–857. doi: 10.1093/jac/27.6.851. [DOI] [PubMed] [Google Scholar]
  7. Nord C. E., Lindmark A., Persson I. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria. Eur J Clin Microbiol Infect Dis. 1993 Aug;12(8):640–642. doi: 10.1007/BF01973648. [DOI] [PubMed] [Google Scholar]
  8. Peterson L. R., Shanholtzer C. J. Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance. Clin Microbiol Rev. 1992 Oct;5(4):420–432. doi: 10.1128/cmr.5.4.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Portnoy D. A. Innate immunity to a facultative intracellular bacterial pathogen. Curr Opin Immunol. 1992 Feb;4(1):20–24. doi: 10.1016/0952-7915(92)90118-x. [DOI] [PubMed] [Google Scholar]
  10. Rudin D. E., Gao P. X., Cao C. X., Neu H. C., Silverstein S. C. Gemfibrozil enhances the listeriacidal effects of fluoroquinolone antibiotics in J774 macrophages. J Exp Med. 1992 Nov 1;176(5):1439–1447. doi: 10.1084/jem.176.5.1439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Skogberg K., Syrjänen J., Jahkola M., Renkonen O. V., Paavonen J., Ahonen J., Kontiainen S., Ruutu P., Valtonen V. Clinical presentation and outcome of listeriosis in patients with and without immunosuppressive therapy. Clin Infect Dis. 1992 Apr;14(4):815–821. doi: 10.1093/clinids/14.4.815. [DOI] [PubMed] [Google Scholar]
  12. Vogt P., Schorn T., Frei U. Ofloxacin in the treatment of urinary tract infection in renal transplant recipients. Infection. 1988 May-Jun;16(3):175–178. doi: 10.1007/BF01644096. [DOI] [PubMed] [Google Scholar]
  13. Wexler H. M., Molitoris E., Finegold S. M. In vitro activity of Bay Y3118 against anaerobic bacteria. Antimicrob Agents Chemother. 1993 Nov;37(11):2509–2513. doi: 10.1128/aac.37.11.2509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. van Ogtrop M. L., Mattie H., Sekh B. R., van Strijen E., van Furth R. Comparison of the antibacterial efficacies of ampicillin and ciprofloxacin against experimental infections with Listeria monocytogenes in hydrocortisone-treated mice. Antimicrob Agents Chemother. 1992 Nov;36(11):2375–2380. doi: 10.1128/aac.36.11.2375. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES